Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
09/2003
09/17/2003CN1442139A Medicinal composition for treating inflammation
09/17/2003CN1121374C Novel trienoic retinoid compounds and method
09/17/2003CN1121238C Novel cyclosporine preparation forms for oral administration of simple composition and high bio availability and process for producing them
09/17/2003CN1121236C Medicine for curing rheumatoid arthritis and preparing method
09/17/2003CN1121214C Use of alicyclic diamines as immunomodulators
09/16/2003US6620847 Copolymer-1 improvements in compositions of copolymers
09/16/2003US6620840 Derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them
09/16/2003US6620832 Substituted ureas
09/16/2003US6620817 Antiinflammatory, antiarthritic agents; autoimmune and rheumatic diseases
09/16/2003US6620811 Isonicotin- and nicotinamide derivatives of benzothiazoles
09/16/2003US6620782 compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or
09/16/2003CA2249009C Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
09/16/2003CA2215695C .beta.-sheet mimetics and use thereof as protease inhibitors
09/16/2003CA2167408C Process for making hiv protease inhibitors
09/16/2003CA2054590C Novel cyclosporins
09/12/2003WO2003075015A2 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
09/12/2003WO2003074711A1 Expression cassette for persistence of expression of a gene of interest in muscle cells
09/12/2003WO2003074681A1 Recombinant spores
09/12/2003WO2003074654A2 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
09/12/2003WO2003074569A2 Bispecific antibody point mutations for enhancing rate of clearance
09/12/2003WO2003074563A2 Means and methods for manipulating hypersensitivity-like responses
09/12/2003WO2003074516A1 Phthalimide carboxylic acid derivatives
09/12/2003WO2003074489A1 Cyclic n-substituted alpha iminocarboxylic acids for selectively inhibiting collagenase
09/12/2003WO2003074483A1 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
09/12/2003WO2003074087A1 Coupling proteins to a modified polysaccharide
09/12/2003WO2003074068A2 Use of soluble fgl2 as an immunosuppressant
09/12/2003WO2003074062A2 Isolation, purification and structural identification of a bioactive component of a water soluble extract of a botanical species for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
09/12/2003WO2003074055A1 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
09/12/2003WO2003074008A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
09/12/2003WO2003073990A2 Treatment for asthma or allergies
09/12/2003WO2003073989A2 Nucleoside 5'-monophosphate mimics and their prodrugs
09/12/2003WO2003073986A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
09/12/2003WO2003073870A1 Health foods having antiallergic effect
09/12/2003WO2003073827A2 Methods of modulating dendritic cells using adjuvants
09/12/2003WO2003065973A8 Multivalent streptococcal vaccine compositions and methods for use
09/12/2003WO2003051828A3 (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
09/12/2003WO2003047524A3 Methods and compositions for modulating the immune system and uses thereof
09/12/2003WO2003045272A3 ORAL IMMUNOSTIMULATION OF MAMMALS, BIRDS, FISH AND REPTILES FROM (1-4) LINKED ß-D-MANNURONIC ACID
09/12/2003WO2003041684A3 Injectable depot compositions and uses thereof
09/12/2003WO2003037268A3 Hepta-, octa- and nonapeptides having antiangiogenic activity
09/12/2003WO2003001877A3 Methods for the diagnosis and treatment of cardiac tissue rejection
09/12/2003WO2002080979A3 Conjugate of hydroxyalkyl starch and an active agent
09/12/2003WO2002080966A3 Method for producing a vaccine containing autologous antibodies
09/12/2003WO2002072830A3 Proteins associated with cell growth, differentiation, and death
09/12/2003WO2002058695A9 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
09/12/2003WO2002040486A3 METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
09/12/2003WO2002032961A8 Novel polypeptides and nucleic acids encoding same
09/12/2003WO2002028424A9 Kyberdrug as autovaccines with immune-regulating effects
09/12/2003WO2002028362A3 Vaccine composition and stabilisation method
09/12/2003WO2001095785A3 Modulation of immune response and methods based thereon
09/12/2003WO2001090197A9 Synthetic peptides and uses therefore
09/12/2003CA2481307A1 Phthalimide carboxylic acid derivatives
09/12/2003CA2478649A1 Means and methods for manipulating hypersensitivity-like responses
09/12/2003CA2478612A1 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
09/12/2003CA2478042A1 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
09/12/2003CA2478011A1 Bispecific antibody point mutations for enhancing rate of clearance
09/12/2003CA2477874A1 Expression cassette for persistence of expression of a gene of interest in muscle cells
09/12/2003CA2477795A1 Nucleoside 5'-monophosphate mimics and their prodrugs
09/12/2003CA2477785A1 Isolation, purification and structural identification of a bioactive component of a water soluble extract of a botanical species for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
09/12/2003CA2477715A1 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient
09/12/2003CA2477449A1 Aminoalkylphosphonates and related compounds as edg receptor agonists
09/12/2003CA2477423A1 Aminoalkylphosphonates and related compounds as edg receptor agonists
09/12/2003CA2477400A1 Treatment for asthma or allergies
09/12/2003CA2477312A1 Use of soluble fgl2 as an immunosuppressant
09/12/2003CA2455447A1 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
09/11/2003WO2003074500A2 N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
09/11/2003US20030171590 Preparation of terfenadine carboxylate metabolite and carebastine derivatives with reduced side effects
09/11/2003US20030171584 6-Substituted pyrido-pyrimidines
09/11/2003US20030171567 Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules, diagnostic and therapeutic uses of said allergens and fragments
09/11/2003US20030171541 Selective binding agents, vectors, host cells, and methods for producing GPCR polypeptides; diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with GPCR polypeptides
09/11/2003US20030171537 Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
09/11/2003US20030171413 Rheumatic diseases; antiarthritic agents; asthma
09/11/2003US20030171404 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
09/11/2003US20030171400 Rheumatic diseases; osteoporosis; multiple sclerosis; autoimmune disease; joint replacements
09/11/2003US20030171389 Anticancer agents; bone disorders; antiarthritic agents
09/11/2003US20030171380 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
09/11/2003US20030171371 For treatment of psoriasis
09/11/2003US20030171365 Inhibitors of the interleukin-1beta conversion enzyme; useful in treatment of inflammatory, auto-immune and neurodegenerative diseases
09/11/2003US20030171361 Treatment of impotence, sexual dysfunction in female, stable, unstable and variant angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis
09/11/2003US20030171359 Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases
09/11/2003US20030171357 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
09/11/2003US20030171337 Useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and
09/11/2003US20030171321 Immunostimulatory oligodeoxynucleotides
09/11/2003US20030171314 Early protection of susceptible animals against foot and mouth disease (FMD) may be achieved by inoculating the animals with a vaccine comprising an interferon DNA sequence. One day after inoculation, animals have been found protected from
09/11/2003US20030171309 Pharmaceutically active pyrrolidine derivatives as bax inhibitors
09/11/2003US20030171280 Compositions and methods for modulation of immune responses
09/11/2003US20030171278 Novel compounds which bind to the human erbB2 gene product (ErbB2, also known as HER2, or c-ErbB-2). In particular aspects, the invention provides for the treatment of disorders characterized by the overexpression of ErbB2 utilizing the
09/11/2003US20030171267 Albumin fusion proteins
09/11/2003US20030171264 Microemulsion preconcentrate; reduced toxicity but high bioavailability; contain cyclosporin A analog ISATx247 (Voclosporin), tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS), medium chain triglyceride (MCT) oil, a Tween" emulsifier, and ethanol
09/11/2003US20030171263 Methods for treating transplant rejection
09/11/2003US20030170859 Gene expression inhibition; for treatment of inflammatory, neurological, cardiovascular, and neoplastic tisssue growth disorders
09/11/2003US20030170839 Type 2 cytokine receptor and nucleic acids encoding same
09/11/2003US20030170831 Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
09/11/2003US20030170812 Interleukin-1beta converting enzyme like cysteine protease
09/11/2003US20030170792 MAGE-3 peptides presented by HLA class ll molecules
09/11/2003US20030170763 Protein antiallergens
09/11/2003US20030170746 Method for screening an agent for ability to inhibit heparanase activity
09/11/2003US20030170331 Plant extract of the olea europaea as no-synthase inhibitor and uses
09/11/2003US20030170329 Cytokine production inhibitors, agents for protecting and promoting liver funtion, anti-inflammatory agents, immunosuppressants, drugs, cosmetics, foods and food materials
09/11/2003US20030170320 Extract is composed of carboxy alkyl esters, especially quinic acid lactone.
1 ... 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 ... 1172